×
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
S&P 500   3,768.78 (-1.48%)
DOW   30,545.40 (-1.77%)
QQQ   279.58 (-0.90%)
AAPL   138.51 (-0.30%)
MSFT   256.63 (-1.14%)
META   162.05 (+1.26%)
GOOGL   2,176.15 (+0.06%)
AMZN   110.68 (+1.02%)
TSLA   663.74 (-2.65%)
NVDA   145.02 (-0.14%)
NIO   21.24 (-0.56%)
BABA   114.53 (-1.27%)
AMD   73.17 (-0.68%)
MU   54.41 (+1.42%)
CGC   2.65 (-5.69%)
T   20.85 (-2.16%)
GE   60.85 (-4.23%)
F   10.82 (-4.42%)
DIS   94.23 (-1.99%)
AMC   12.74 (-5.84%)
PFE   50.58 (-3.31%)
PYPL   71.64 (+0.34%)
NFLX   178.41 (-0.86%)
NASDAQ:AFMD

Affimed Stock Forecast, Price & News

$2.93
+0.12 (+4.27%)
(As of 07/5/2022 11:39 AM ET)
Add
Compare
Today's Range
$2.76
$2.95
50-Day Range
$2.27
$4.06
52-Week Range
$2.23
$7.65
Volume
21,640 shs
Average Volume
1.18 million shs
Market Capitalization
$361.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Affimed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
241.3% Upside
$10.00 Price Target
Short Interest
Healthy
3.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.95
Upright™ Environmental Score
News Sentiment
0.40mentions of Affimed in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.72) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.06 out of 5 stars

Medical Sector

446th out of 1,428 stocks

Pharmaceutical Preparations Industry

206th out of 680 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive AFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Affimed and its competitors with MarketBeat's FREE daily newsletter.

Affimed logo

About Affimed (NASDAQ:AFMD) Stock

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

AFMD Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AFMD
Employees
197
Year Founded
N/A

Company Calendar

Last Earnings
6/01/2022
Today
7/05/2022
Next Earnings (Estimated)
9/14/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+241.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
6 Analysts

Profitability

Net Income
$-68,060,000.00
Net Margins
-215.31%
Pretax Margin
-207.09%

Debt

Sales & Book Value

Annual Sales
$47.76 million
Book Value
$1.30 per share

Miscellaneous

Free Float
N/A
Market Cap
$361.62 million
Optionable
Optionable
Beta
2.45














Affimed Frequently Asked Questions

Should I buy or sell Affimed stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Affimed in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Affimed stock.
View analyst ratings for Affimed
or view top-rated stocks.

What is Affimed's stock price forecast for 2022?

6 Wall Street analysts have issued 1 year target prices for Affimed's stock. Their AFMD stock forecasts range from $7.00 to $12.00. On average, they expect Affimed's share price to reach $10.00 in the next year. This suggests a possible upside of 241.3% from the stock's current price.
View analysts' price targets for Affimed
or view top-rated stocks among Wall Street analysts.

How has Affimed's stock performed in 2022?

Affimed's stock was trading at $5.52 on January 1st, 2022. Since then, AFMD stock has decreased by 46.9% and is now trading at $2.93.
View the best growth stocks for 2022 here
.

When is Affimed's next earnings date?

Affimed is scheduled to release its next quarterly earnings announcement on Wednesday, September 14th 2022.
View our earnings forecast for Affimed
.

How were Affimed's earnings last quarter?

Affimed (NASDAQ:AFMD) announced its earnings results on Wednesday, June, 1st. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.18) by $0.02. The biopharmaceutical company earned $8.98 million during the quarter, compared to analyst estimates of $9.93 million. Affimed had a negative net margin of 215.31% and a negative trailing twelve-month return on equity of 58.18%. During the same quarter last year, the firm earned $0.01 earnings per share.
View Affimed's earnings history
.

Who are Affimed's key executives?

Affimed's management team includes the following people:
  • Dr. Adi Hoess, CEO, MD & Member of Management Board (Age 61, Pay $821.42k)
  • Mr. Angus W. Smith, CFO & Member of Management Board (Age 40, Pay $591.67k)
  • Dr. Wolfgang Fischer, MD, COO & Member of Management Board (Age 58, Pay $647.28k)
  • Ms. Denise Mueller, Chief Bus. Officer & Member of Management Board (Age 53, Pay $564.4k)
  • Dr. Andreas Harstrick M.D., Chief Medical Officer & Member of Management Board (Age 61, Pay $537.12k)
  • Dr. Arndt J. G. Schottelius M.D., Ph.D., Chief Scientific Officer & Member of Management Board (Age 56, Pay $649.37k)
  • Prof. Melvyn Little, Founder & Consultant
  • Mr. Michael Wolf, Head of Fin. & Admin. (Age 55)
  • Mr. Alexander Fudukidis, Head of Investor Relations
  • Dr. Uwe Reusch, Head of Cell Culture

What other stocks do shareholders of Affimed own?

What is Affimed's stock symbol?

Affimed trades on the NASDAQ under the ticker symbol "AFMD."

How do I buy shares of Affimed?

Shares of AFMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Affimed's stock price today?

One share of AFMD stock can currently be purchased for approximately $2.93.

How much money does Affimed make?

Affimed (NASDAQ:AFMD) has a market capitalization of $361.62 million and generates $47.76 million in revenue each year. The biopharmaceutical company earns $-68,060,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does Affimed have?

Affimed employs 197 workers across the globe.

How can I contact Affimed?

Affimed's mailing address is TECHNOLOGIEPARK IM NEUENHEIMER FELD 582, HEIDELBERG 2M, 69120. The official website for Affimed is www.affimed.com. The biopharmaceutical company can be reached via phone at 496221674360, via email at ir@affimed.com, or via fax at 49-6221-653-0777.

This page (NASDAQ:AFMD) was last updated on 7/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.